Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
3.81%
operating margin TTM
11.4%
revenue TTM
204.88 Million
revenue per share TTM
1.19$
valuation ratios | |
|---|---|
| pe ratio | 116.03 |
| peg ratio | 0.01 |
| price to book ratio | 107.67 |
| price to sales ratio | 4.50 |
| enterprise value multiple | 32.36 |
| price fair value | 107.67 |
profitability ratios | |
|---|---|
| gross profit margin | 81.59% |
| operating profit margin | 11.4% |
| pretax profit margin | 3.81% |
| net profit margin | 3.81% |
| return on assets | 3.06% |
| return on equity | 735.0% |
| return on capital employed | 13.13% |
liquidity ratios | |
|---|---|
| current ratio | 2.12 |
| quick ratio | 1.50 |
| cash ratio | 0.94 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 467.42 |
| operating cycle | 532.68 |
| days of payables outstanding | 72.20 |
| cash conversion cycle | 460.48 |
| receivables turnover | 5.59 |
| payables turnover | 5.06 |
| inventory turnover | 0.78 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.10 |
| debt equity ratio | 2.87 |
| long term debt to capitalization | 0.70 |
| total debt to capitalization | 0.74 |
| interest coverage | 1.25 |
| cash flow to debt ratio | 1.30 |
cash flow ratios | |
|---|---|
| free cash flow per share | 0.28 |
| cash per share | 0.66 |
| operating cash flow per share | 0.28 |
| free cash flow operating cash flow ratio | 0.97 |
| cash flow coverage ratios | 1.30 |
| short term coverage ratios | 7.74 |
| capital expenditure coverage ratio | 37.33 |
Frequently Asked Questions
When was the last time Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reported earnings?
Xeris Biopharma Holdings, Inc. (XERS) published its most recent earnings results on 07-05-2026.
What is Xeris Biopharma Holdings, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)'s trailing twelve months ROE is 735.0%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Xeris Biopharma Holdings, Inc. (XERS) currently has a ROA of 3.06%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did XERS's net profit margin stand at?
XERS reported a profit margin of 3.81% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is XERS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 2.12 in the most recent quarter. The quick ratio stood at 1.50, with a Debt/Eq ratio of 2.87.